(Q38494601)

English

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy

scientific article published on May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 September 2017

Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy (English)

1 reference

Europe PubMed Central

3 September 2017

0 references

type 2 diabetes

1 reference

based on heuristic

inferred from title

Henning Beck-Nielsen

4

object named as

Henning Beck-Nielsen

0 references

author name string

Kim Henriksen

1

1 reference

Europe PubMed Central

3 September 2017

Inger Byrjalsen

2

1 reference

Europe PubMed Central

3 September 2017

Per Qvist

3

1 reference

Europe PubMed Central

3 September 2017

Henning Beck-Nielsen

4

1 reference

Europe PubMed Central

3 September 2017

Gitte Hansen

5

1 reference

Europe PubMed Central

3 September 2017

Bente J Riis

6

1 reference

Europe PubMed Central

3 September 2017

Hans Perrild

7

1 reference

Europe PubMed Central

3 September 2017

Ole Lander Svendsen

8

1 reference

Europe PubMed Central

3 September 2017

Jeppe Gram

9

1 reference

Europe PubMed Central

3 September 2017

Morten A Karsdal

10

1 reference

Europe PubMed Central

3 September 2017

Claus Christiansen

11

1 reference

Europe PubMed Central

3 September 2017

BALLET Trial Investigators

12

1 reference

Europe PubMed Central

3 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 May 2011

1 reference

Europe PubMed Central

3 September 2017

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

3 September 2017

27

1 reference

Europe PubMed Central

3 September 2017

4

1 reference

Europe PubMed Central

3 September 2017

392-401

1 reference

Europe PubMed Central

3 September 2017

Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

10-year follow-up of intensive glucose control in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Genome-wide profiling of PPARgamma:RXR and RNA polymerase II occupancy reveals temporal activation of distinct metabolic pathways and changes in RXR dimer composition during adipogenesis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Suppression of PPAR transactivation switches cell fate of bone marrow stem cells from adipocytes into osteoblasts

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

PPARs: therapeutic targets for metabolic disease

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Addition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, para

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Insulin treatment and the problem of weight gain in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

The effect of thiazolidinediones on BMD and osteoporosis

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

The risk of fractures associated with thiazolidinediones: a self-controlled case-series study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Diagnosis of heart failure.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17).

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Thiazolidinediones and clinical outcomes in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

21 January 2018

Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.1187

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.1187

1 reference

Europe PubMed Central

3 September 2017

1 reference

Europe PubMed Central

3 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38494601&oldid=1762278590"